Phospholipase A2 Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
1.1. Discovery of the Phospholipase A2 Superfamily Phospholipases represent one of the
earliest enzyme activities to be identified and studied, and the phospholipase A2 (PLA2) …
earliest enzyme activities to be identified and studied, and the phospholipase A2 (PLA2) …
[HTML][HTML] Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches
Small, dense low density lipoprotein (sdLDL) represents an emerging cardiovascular risk
factor, since these particles can be associated with cardiovascular disease (CVD) …
factor, since these particles can be associated with cardiovascular disease (CVD) …
Lipoprotein-associated phospholipase A (2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.
A Thompson, P Gao, L Orfei, S Watson… - Lancet (London …, 2010 - europepmc.org
Background Lipoprotein-associated phospholipase A (2)(Lp-PLA (2)), an inflammatory
enzyme expressed in atherosclerotic plaques, is a therapeutic target being assessed in trials …
enzyme expressed in atherosclerotic plaques, is a therapeutic target being assessed in trials …
[HTML][HTML] Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic “power station”
L Trapani, M Segatto, V Pallottini - World journal of hepatology, 2012 - ncbi.nlm.nih.gov
Cholesterol plays several structural and metabolic roles that are vital for human biology. It
spreads along the entire plasma membrane of the cell, modulating fluidity and concentrating …
spreads along the entire plasma membrane of the cell, modulating fluidity and concentrating …
Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 …
M O'Donoghue, DA Morrow, MS Sabatine, SA Murphy… - Circulation, 2006 - Am Heart Assoc
Background—Lipoprotein-associated phospholipase A2 (Lp-PLA2) is associated with the
risk of cardiovascular (CV) events in population-based studies. The prognostic value of Lp …
risk of cardiovascular (CV) events in population-based studies. The prognostic value of Lp …
The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart …
ER Mohler, CM Ballantyne, MH Davidson… - Journal of the American …, 2008 - jacc.org
Objectives: This study examined the effects of darapladib, a selective lipoprotein-associated
phospholipase A2 (Lp-PLA2) inhibitor, on biomarkers of cardiovascular (CV) risk …
phospholipase A2 (Lp-PLA2) inhibitor, on biomarkers of cardiovascular (CV) risk …
Oxidized phospholipids and lipoprotein‐associated phospholipase A2 (Lp‐PLA2) in atherosclerotic cardiovascular disease: An update
Inflammation and oxidative stress conditions lead to a variety of oxidative modifications of
lipoprotein phospholipids implicated in the occurrence and development of atherosclerotic …
lipoprotein phospholipids implicated in the occurrence and development of atherosclerotic …
Τhe role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma
CC Tellis, AD Tselepis - Biochimica et Biophysica Acta (BBA)-Molecular …, 2009 - Elsevier
Platelet-activating factor (PAF) acetylhydrolase exhibits a Ca2+-independent phospholipase
A2 activity and degrades PAF as well as oxidized phospholipids (oxPL). Such phospholipids …
A2 activity and degrades PAF as well as oxidized phospholipids (oxPL). Such phospholipids …
Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects
M Persson, B Hedblad, JJ Nelson… - … , and vascular biology, 2007 - Am Heart Assoc
Background—To explore potential interrelationships between lipoprotein-associated
phosholipase A2 (Lp-PLA2), the metabolic syndrome (MetS), and incident cardiovascular …
phosholipase A2 (Lp-PLA2), the metabolic syndrome (MetS), and incident cardiovascular …
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass …
MH Davidson, KC Maki, H Bays, R Carter… - Journal of clinical …, 2009 - Elsevier
BACKGROUND: Prescription omega-3-acid ethyl esters (P-OM3) often are used for
hypertriglyceridemic patients receiving statin therapy who have residual increases in …
hypertriglyceridemic patients receiving statin therapy who have residual increases in …